RGCC
RGCC Group is a Swiss precision medicine company that delivers personalized cancer diagnostics through liquid biopsy and biomarker analysis via RGCC International, drug discovery services via Welmedis, and direct-to-consumer health testing via Biocentaur, serving cancer patients, healthcare providers, and pharmaceutical clients globally.
- Company typePrivate
- Founded2004
- HeadquartersZug, Switzerland
- Headcount101–250
- GTM typeB2B and B2C
- OfferingServices
What RGCC does
RGCC Group is a Swiss precision medicine company founded in 2004 by genetics pioneer Dr. Ioannis Papasotiriou and headquartered in Zug, Switzerland. The company operates through three integrated divisions: RGCC International provides personalized cancer diagnostics using liquid biopsy technology, circulating tumor cell (CTC) analysis, circulating tumor DNA (ctDNA) analysis, and biomarker profiling; Welmedis develops targeted therapeutics and conducts drug discovery using the RGCC target identification platform, identifying novel targets for small-molecule therapeutics; and Biocentaur offers direct-to-consumer molecular biology tests for disease risk assessment, diagnosis, and treatment response determination. In April 2024, RGCC launched Onco-D-clare, a cancer detection test that combines molecular biology with artificial neural networks to identify cancer before symptoms appear.
RGCC serves four primary customer segments: cancer patients and survivors seeking personalized treatment insights, healthcare providers and oncologists who order diagnostic tests and integrate results into treatment plans, pharmaceutical and biotechnology companies leveraging the company's CRO services and target identification platform, and health-conscious individuals accessing Biocentaur's consumer testing services. The company distributes through regional web platforms serving North America (myrgcc.com), Southeast Asia (rgccsea.com), and European markets (rgcc-international.com), combining direct-to-consumer self-serve ordering with direct enterprise sales for clinical research and pharmaceutical collaborations. The company employs 51-100 staff and operates under GDPR, Swiss FADP, and GMP practices.
Revenue mechanics span four streams: recurring diagnostic testing services (RGCC International), one-time consumer health tests (Biocentaur), licensing and royalty arrangements for drug discovery (Welmedis), and professional services for CRO engagements. Pricing is quote-based and not publicly disclosed. RGCC is founder-owned and bootstrapped, having consistently declined external funding since 2004 to preserve scientific independence. The company competes in a market (tumor marker testing) projected to reach $27.23 billion by 2030 at a 7.9% CAGR, driven by demand for early cancer detection, precision oncology adoption, and companion diagnostics.
RGCC firmographics
Firmographics- Name
- RGCC
- Legal name
- RGCC International GmbH
- Website
- https://rgcc-group.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- RGCC Group is a Swiss precision medicine company that delivers personalized cancer diagnostics through liquid biopsy and biomarker analysis via RGCC International, drug discovery services via Welmedis, and direct-to-consumer health testing via Biocentaur, serving cancer patients, healthcare providers, and pharmaceutical clients globally.
- Ownership category
- akta.pro rank
RGCC industry classification
Industry- Product category
- Precision Oncology Diagnostics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD), Clinical Research & Trial Central Laboratories (HLAFAMAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where RGCC is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
RGCC business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Cancer Diagnostic Testing Services: RGCC International generates revenue through personalized blood tests (liquid biopsy) and cancer diagnostic services, providing tumor profiling and biomarker analysis for individual patients
- Consumer Health Testing: Biocentaur division offers direct-to-consumer disease risk assessment, diagnostic, and treatment response tests for preventive healthcare decisions
- Drug Discovery and Therapeutic Development: Welmedis division develops targeted therapeutics and provides drug discovery services using RGCC's target identification platform, identifying novel targets for small-molecule therapeutics
- Clinical Research Services: CRO services accelerating clinical trial readiness and regulatory compliance across Europe, supporting pharmaceutical and biotechnology clients
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Diagnostic testing services offered through RGCC International, Biocentaur, and regional platforms |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
RGCC product offering
Product offeringCore offering
RGCC provides advanced cancer diagnostics through proprietary liquid biopsy technology, including circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis for clinicians and patients. The company operates three divisions: RGCC International (clinical cancer diagnostics for healthcare providers), Welmedis (drug discovery and pharmaceutical development services), and Biocentaur (consumer-directed health and genetic tests).
Product overview
RGCC Group operates as a fully integrated healthcare company with three main business divisions. RGCC International provides personalized cancer testing through liquid biopsies and biomarker analyses. Welmedis focuses on drug discovery and targeted therapeutics development. Biocentaur offers disease diagnostic and genetic predisposition tests. In April 2024, RGCC launched Onco-D-clare, an AI-powered cancer detection test that combines molecular biology with artificial neural networks to identify cancer before symptoms appear.
Differentiator
Problem solved
Functional benefit
Brands
- Onco-D-clare: Cancer detection test combining molecular biology with artificial neural networks to identify cancer before symptoms appear, launched April 2024
Products and services
- RGCC International Cancer Diagnostics
Quantifiable outcome
- Onco-D-clare can identify cancer before symptoms appear
- +1 more outcomes
Companies that use RGCC
Customer profileSegments4 records
Ideal customer profiles3 records
RGCC technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
RGCC partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
RGCC competitors and assessment
Company assessmentDirect peers
- Guardant Health: Guardant Health is a leading liquid-biopsy company offering oncology liquid biopsy tests (Guardant360, Guardant Reveal for MRD) for tumor profiling and recurrence monitoring—directly overlapping RGCC's liquid-biopsy diagnostic franchise and oncology customer base.
- Natera: Natera offers Signatera, a tumor-informed ctDNA MRD test, alongside broader oncology and reproductive health diagnostics. It directly competes with RGCC in oncology liquid biopsy and shares the same customer base of oncologists and clinical researchers.
- Exact Sciences: Exact Sciences (Cologuard, Oncotype DX, Oncodetect MRD test) is a major cancer diagnostics competitor covering screening, tumor profiling, and MRD—the same continuum of use cases that RGCC International targets.
- Tempus AI: Tempus AI combines molecular profiling with AI/ML-driven insights for oncology and is increasingly competing in liquid biopsy. It mirrors RGCC's positioning of pairing molecular data with artificial intelligence for clinical decision support.
- Caris Life Sciences: Caris offers molecular profiling (MI Profile, MI Cancer Seek) plus AI-driven analytics. It directly overlaps RGCC's liquid-biopsy + biomarker + AI positioning in precision oncology.
- NeoGenomics: NeoGenomics operates a global oncology-focused clinical laboratory business offering tumor profiling and liquid biopsy services, directly comparable to RGCC International's clinical-diagnostics service line.
Broad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) offers comprehensive genomic profiling of solid tumors via FoundationOne CDx. It competes directly with RGCC's tumor-profiling services while operating at significantly larger scale and with deep pharma partnership distribution.
- BIO-Techne: BIO-Techne provides life-science research reagents, including exosome diagnostics (ExoDx) for prostate cancer, and serves as a broader life-science tools incumbent with adjacent oncology-diagnostic exposure to RGCC's biomarker work.
Emerging players
- Personalis: Personalis offers ultra-sensitive ctDNA-based MRD testing (NeXT Personal) and tumor profiling, overlapping RGCC's liquid biopsy diagnostics, particularly in the MRD subsegment.
- VolitionRx: VolitionRx is developing blood-based cancer diagnostic tests using nucleosome-based biomarkers. It is a smaller competitor in liquid-biopsy cancer detection with overlapping early-detection ambitions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RGCC social profiles
Digital presenceRGCC compliance and trust
Trust signalCompliance3 records
RGCC financial estimates
Financial estimateRevenue estimate
Valuation estimate
RGCC leadership team
Management profileNumber of profiles
Profiles1 record
RGCC subsidiaries and ownership
Company hierarchySubsidiaries3 records
RGCC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RGCC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RGCC
What does RGCC do?
RGCC provides advanced cancer diagnostics through proprietary liquid biopsy technology, including circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis for clinicians and patients. The company operates three divisions: RGCC International (clinical cancer diagnostics for healthcare providers), Welmedis (drug discovery and pharmaceutical development services), and Biocentaur (consumer-directed health and genetic tests).
Is RGCC a public or private company?
RGCC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RGCC founded?
RGCC was founded in 2004. It employs 101 to 250 people.
Where is RGCC based?
RGCC is headquartered in Zug, Switzerland, in the Europe region.
How does RGCC make money?
Four revenue lines are on record. Cancer Diagnostic Testing Services are the primary driver. The others are consumer Health Testing, drug Discovery and Therapeutic Development and clinical Research Services.
Who are RGCC's main competitors?
Direct peers on record are Guardant Health, Natera, Exact Sciences, Tempus AI, Caris Life Sciences and NeoGenomics. Broad incumbents are Foundation Medicine and BIO-Techne. Emerging players are Personalis and VolitionRx.
Does RGCC have an API?
No public API is recorded for RGCC.
What industry is RGCC in?
RGCC's product category is Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 621511 and its SIC code is 8071.